Arbeitsgruppe Hepatobiliäre Tumoren - Studien
Frühes HCC, kurativ, Erstlinie

AIO-assoziierte Studie Für weitere Zentren offen   zur Studie
  AIO-HEP-0417/ass: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC) (IMMULAB)
  --- in Vorbereitung, Studienstart noch offen, geplant Q2/2018 ---
HCC, periinterventionelle Studie, Erstlinie

AIO-Studie
  zur Studie
  AIO-HEP-0217: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) (IMMUTACE)
  --- in Vorbereitung, Studienstart noch in 2018 geplant, weitere Zentren evtl. auf Warteliste---
HCC, definitive Therapie im intermediären Stadium

AIO-assoziierte Studie Für weitere Zentren offen   zur Studie
  AIO-HEP-0317/ass: TACE followed by systemic therapy compared to continuous TACE in intermediate stage hepatocellular carcinoma (HCC) (TACEnd) – a randomized multicentre phase III trial of the AIO
  --- in Vorbereitung, Studienstart noch offen ---
Fortgeschrittenes HCC, First line

AIO-assoziierte Studie Für weitere Zentren offen   zur Studie
  AIO-HEP-0218/ass: An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC) [IMMUNIB]
  --- in Vorbereitung, FPI Q3/2018 geplant, weitere Zentren sehr gerwünscht ---
Cholangio- and Gallbladder Carcinoma, Erstlinie

AIO-Studie
www.clinicaltrials.gov zur Studie
  AIO-HEP-0117: A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma [IMMUCHEC]
  --- in Vorbereitung, Studienstart geplant Q2/2018, weitere Zentren evtl. auf Warteliste ---

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-YMO/HEP-0315: Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial (NIFE)
  ---in Rekrutierung---
Cholangiozelluläres Karzinom, Zweitlinie

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-HEP-0116: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine or gemcitabine containing therapies (NALIRICC)
  ---in Rekrutierung---
Cholangiokarzinom (intra- und extrahepatisch), Gallenblasenkarzinom, Zweitlinie

AIO-Studie   www.drks.de zur Studie

AIO-YMO/HEP-0316: 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study (IRIBIL)
  ---in Rekrutierung---
Cholangiozelluläres Karzinom

AIO-Studie   www.clinicaltrials.gov zur Studie

AIO-HEP-0112: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1). A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial
  ---in Rekrutierung---
Gallbladder Carcinoma Platform - Registerstudie

AIO-assoziierte Studie Für weitere Zentren offen   zur Studie

AIO-HEP-0118/ass: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – A phase III study utilizing the German Registry of Incidental Gallbladder Carcinoma Platform (GR)
– The AIO/ CALGP/ ACO- GAIN-Trial -
  ---in Vorbereitung, Studienstart noch in 2018 geplant, weitere Zentren sind sehr erwünscht! ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 20.06.2018